Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EPS (Weighted Average and Diluted) (2016 - 2025)

Cytosorbents' EPS (Weighted Average and Diluted) history spans 9 years, with the latest figure at -$0.09 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.09 for Q4 2025, up 35.71% from a year ago — trailing twelve months through Dec 2025 was -$0.13 (up 65.79% YoY), and the annual figure for FY2025 was -$0.13, up 65.79%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.09 at Cytosorbents, down from -$0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.03 in Q2 2025 to a low of -$0.28 in Q3 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.12 (2021), against an average of -$0.13.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 1331.96% in 2021, then surged 137.5% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then soared by 92.0% to -$0.02 in 2022, then crashed by 500.0% to -$0.12 in 2023, then dropped by 16.67% to -$0.14 in 2024, then soared by 35.71% to -$0.09 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.09, -$0.05, and $0.03 for Q4 2025, Q3 2025, and Q2 2025 respectively.